C3N-03222
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 72.90896646
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.320
- G2M_CHECKPOINT+0.290
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.220
- HYPOXIA+0.220
- ESTROGEN_RESPONSE_EARLY+0.210
- SPERMATOGENESIS+0.210
- MITOTIC_SPINDLE+0.200
- MYOGENESIS+0.190
- APICAL_JUNCTION+0.170
- ANDROGEN_RESPONSE+0.140
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.630
- INTERFERON_GAMMA_RESPONSE-0.520
- ALLOGRAFT_REJECTION-0.450
- IL6_JAK_STAT3_SIGNALING-0.380
- PANCREAS_BETA_CELLS-0.340
- INFLAMMATORY_RESPONSE-0.330
- COMPLEMENT-0.300
- IL2_STAT5_SIGNALING-0.280
- KRAS_SIGNALING_UP-0.280
- HEDGEHOG_SIGNALING-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-K4-A6MB-01A-11R-A31N-07 | — | — | 0.792 |
| 2 | TCGA-OR-A5KO-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.787 |
| 3 | SRR25617914 | — | C | 0.756 |
| 4 | SRR8518424 | — | C | 0.748 |
| 5 | BSR_19_0079_A1_S53 | — | B | 0.747 |
| 6 | ERR2278878 | — | — | 0.742 |
| 7 | SRR8613771 | — | E | 0.739 |
| 8 | SRR8518326 | — | E | 0.738 |
| 9 | s0095123 | — | — | 0.738 |
| 10 | 20120162.TNBC | — | E | 0.733 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 25 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.220 | Inavolisib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.140 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.140 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.120 | Inavolisib | — uncovered |
| PEROXISOME | 0.110 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.090 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.060 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.050 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.040 | Remibrutinib | — uncovered |